Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Post by Savage97on Sep 04, 2020 10:41am
206 Views
Post# 31510058

Canopy Growth’s CEO & Former Chairman Klein vs Simon

Canopy Growth’s CEO & Former Chairman Klein vs Simon

CGC has managed to burn through $3 billion of cash while diluting shareholders by 20%.  CGC has seen weak gross margins: past quarter saw gross margins of 6%.  Selling, general, & administrative expenses totaled $135.4 million:  $16 million higher than total revenues. CGC has decided to go the direction of less-clarity, as in this most recent quarter it has decided to stop disclosing kilograms sold and average selling prices.

 

Aphria's 2020 fiscal year highlights:

Adjusted EBITDA grew from $209,000 to CA$8.6 million, with 52.9% gross margin in selling cannabis.  Revenue grew by 129% to CA$543.3 million, compared with CA$237.1 million in 2019. Aphria's cash cost decreased, sales were up 18.4% from the prior-year period.  Aphria is ranked No. 1 in the adult-use recreational market in Canada and the market leader for Vapes.  Aphria expanding into Germany with in country production facility and exports Europe from Aphria One.
<< Previous
Bullboard Posts
Next >>